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Abstract Erythropoietin (EPO) promotes viability, prolifera-
tion and differentiation of mammalian erythroid progenitor cells
via its specific cell surface receptor (EPO-R). We have
previously shown that truncated EPO-Rs containing 267 amino
acids or less were defective in internalization of 125I-EPO,
whereas internalization via a receptor derivative containing 276
amino acids was unaffected, thus directing focus to the nine
amino acid residues FEGLFTTHK at positions 268^276 [Levin,
Cohen, Supino, Yoshimura, Watowich, Neumann, FEBS Lett.
427 (1998) 164^170]. Here, a panel of EPO-R mutants was
generated to determine the role of these residues in EPO
endocytosis, down regulation of cell surface receptors and EPO-
mediated signaling. While linking amino acid residues 268^276
to a truncated EPO-R (v+9 EPO-R) conferred both ligand
uptake and ligand-independent down regulation of the respective
receptor from the cell surface, Phe 272 was crucial for EPO
endocytosis but not for ligand-independent down regulation.
Additional receptor motifs probably play a role in EPO
endocytosis and receptor down-regulation, as these processes
were not adversely impaired in v268^276 EPO-R. A central role
of residues 268^276, in particular Phe, was demonstrated by the
inability of v268^276 and F268,272A EPO-Rs to support EPO-
mediated signal transduction. ß 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Proliferation of immature red blood cells and their di¡er-
entiation into mature erythrocytes are mediated by binding of
erythropoietin (EPO) to its cell surface receptor (EPO-R) a
member of the superfamily of cytokine receptors [1]. Unlike
receptor Tyr kinases, the cytosolic domain of cytokine recep-
tors is devoid of kinase activity and is phosphorylated by
Janus kinases (JAKs) following ligand binding [2]. The low
cell surface expression of EPO-R suggests that a tight control
mechanism operates to regulate erythroid proliferation and
di¡erentiation in response to physiological levels of EPO
under normal or hypoxic conditions [3,4]. Receptor internal-
ization and ligand-mediated endocytosis are pivotal processes,
which regulate cell surface receptors. Accumulating evidence
suggests that endocytosis of membrane proteins is mediated
by speci¢c sequence(s) in their cytosolic domains, which inter-
act with auxiliary cellular molecules [5^7]. The sequences in-
clude di-Leu-based motifs [8^10], Tyr-based motifs [6,11] and
a third group of sequences containing various features such as
clustered acidic residues [12], or mono amino acid-based mo-
tifs [13].
The capacity of a series of cytoplasmic tail truncated EPO-
R variants to internalize 125I-EPO was measured by us [14]
and others [15] demonstrating that a membrane proximal cy-
tosolic domain of the EPO-R was the minimal region required
for receptor-mediated ligand internalization. Ligand binding
to the EPO-R was found to accelerate the rate of receptor
internalization of cell surface receptor from T1=2 of 3 h in
the absence of ligand to 15 min in its presence [16]. The con-
tribution of selected EPO-R cytosolic regions to ligand-inde-
pendent internalization of the EPO-R is not known. The
present study was designed to examine the involvement of
the cytosolic sequence FEGLFTTHK (amino acid residues
268^276) in the internalization of EPO via cell surface EPO-
R, in constitutive down regulation of surface receptors and in
EPO-mediated signal transduction. The results showed that
the addition of amino acid residues 268^276 to an EPO-R
which is devoid of the cytosolic domain (v+9 EPO-R) im-
proved the capacity of the respective receptor to endocytose
125I-EPO as well as conferred its constitutive down regulation
from the cell surface. Mutation of Phe to Ala at position 272
(v+9 (F272A) EPO-R) adversely a¡ected receptor-mediated
ligand endocytosis, but did not alter the T1=2 of cell surface
receptor in the absence of ligand, suggesting that these two
processes require distinct structural features of the receptor.
Excision of amino acids 268^276 from wild type (wt) EPO-R
did not impair 125I-EPO internalization via the receptor, nor
alter the T1=2 of cell surface receptor in the absence of ligand,
yet it abrogated binding of the receptor to JAK2 and EPO-
mediated proliferation of Ba/F3 cells. Phe residues within the
segment 268^276 seem to play a major role in EPO-mediated
signal transduction.
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2. Materials and methods
2.1. Materials
Puri¢ed recombinant Human EPO was a kind gift from Kirin Inc.,
Japan. All other materials were obtained from sources previously
listed [17].
2.2. Antibodies
Rabbit antibodies directed against the extracellular domain of the
murine EPO-R [18] were used at 1:500 and 1:2000 dilutions for im-
munoprecipitations and Western blot analysis, respectively, of EPO-R
cloned in pXM and expressed in COS 7 or Ba/F3 cells. Antibodies
against JAK2 and EPO-R from Upstate Biotechnology were used for
analysis of Ba/F3 cells stably transfected with EPO-R cDNAs cloned
in the bicistronic retroviral vector, pMX-IRES-GFP. Anti-P-Tyr anti-
body (4G10), was obtained from Upstate Biotechnology.
2.3. Construction of mutant EPO-R cDNAs
1^257, 1^267 and 1^276 EPO-Rs were previously described [14].
The cDNAs of v268^276 or v256^267 EPO-Rs were generated using
the Altered SitesII in Vitro Mutagenesis System (Promega) [19] and
the following two oligonucleotides, respectively: (A) 5P-ACGC-
TGCAGCAGCCACAGCTGGAAGTTACCCTCGCTCTCTGGGC-
TTGGGATGCCAGGCCA-3P ; (B) 5P-CTTGTGGGTGGTGAAGA-
GACCCTCAAACTGCTGCAGAGTCCGGCGGTGGGACAG-3P.
EPO-R mutants (v+9, v+9 (F272A), 1^276 (F272A)) were prepared
by the PCR methodology, using the forward primer 5P-GAGTCGG-
TACCTGAAGCTAGGGCTGC-3P, which contains a KpnI site in its
5P-end. v+9 EPO-R (an EPO-R truncated at amino acid 255 onto
which the sequence motif 268^276 was attached) was generated using
v256^267 EPO-R as a template and the reverse primer 5P-ATGCG-
GAATTCCTACTTGTGGGTGGTGAAGAGACC-3P. v+9(F272A)
and 1^276 (F272A) EPO-Rs were generated using v+9 and 1^276
EPO-Rs as templates, respectively and the reverse primer 5P-ATGC-
GGAATTCCTACTTGTGGGTGGTGGCGAGACCCTCAAAC-3P.
Both reverse primers contained an EcoRI site for subcloning into the
pXM vector.
F268,272A EPO-R was generated by using the forward primer 5P-
AGATCTGGCCTGGCATCCCAAGCCCAGAGAGCGAGGCTG-
AGGGTCTCGCCA-3P along with the reverse primer from the EPO-
R sequence 5P-GGCTGGATCCCTAGGAGCAGGCCAC-3P to gen-
erate a BglII^EcoRI PCR fragment which was exchanged with the
corresponding region of the wt EPO-R cDNA in pXM.
Wt EPO-R, v268^276 and v256^267 EPO-Rs were also cloned in
the pMX-IRES-GFP bicistronic retroviral vector upstream of the in-
ternal ribosome entry site (IRES) [20,21]. All constructs were veri¢ed
by sequencing.
2.4. Cell culture and transfection
COS 7 cells were grown and transfected as previously described
[22].
Ba/F3 cell lines stably expressing v268^276 or v256^267 EPO-Rs
cloned in pXM were generated as described [23]. Ba/F3 cell lines
stably expressing wt or v268^276 or v256^267 EPO-Rs and green
£uorescent protein (GFP) were obtained as described [24]. It was
previously shown [20,21] that over a 50-fold range there is correlation
between the level of GFP (monitored by FACS) and that of the EPO-
R. Hence, cells were sorted by FACS to a similar amount of GFP,
indicating that they express the corresponding EPO-R mutants to a
similar level.
Ba/F3 cell lines stably expressing wt EPO-R cDNA were main-
tained in RPMI supplemented with 10% FCS (v/v) and 0.25 U/ml
EPO or 10% conditioned medium from WEHI 3B cells as a source
of interleukin (IL)-3 for mutant EPO-Rs.
2.5. Iodination of EPO, binding and internalization
Recombinant EPO labeling and internalization were determined as
described [22,25], respectively. T1=2 of cell surface EPO-R was deter-
mined essentially according to [16,26]. COS 7 cells transfected with
EPO-R cDNAs were incubated in the presence of 100 Wg/ml cyclo-
heximide (CHX) at 37‡C. Cells were collected at di¡erent time points
after CHX addition and incubated over night at 4‡C with 125I-EPO to
determine the levels of cell surface EPO-Rs.
2.6. Metabolic labeling, immunoprecipitation and Western blot analysis
COS 7 cells transiently transfected with EPO-R cDNAs (2U106
cells for each time point) were labeled with [35S]Cys/Met for 30 min,
solubilized and subjected to immunoprecipitation as described [27].
Western blot analysis was performed as described [24].
2.7. EPO-dependent proliferation
Cell proliferation in response to EPO was determined by methyl-
thiazol^tetrazolium analysis [28].
3. Results
3.1. 125I-EPO internalization mediated by EPO-R mutants
A panel of EPO-R mutants was constructed to determine
whether amino acid residues (FEGLFTTHK) at position 268^
276 are su⁄cient to mediate internalization of EPO and
whether individual amino acid residues in this sequence are
required for this process (Fig. 1A).
We have previously shown that 1^267 EPO-R (Fig. 1A) is
Fig. 1. EPO-R variants and their expression in COS 7 cells. A: Schematic representation of EPO-Rs. The EPO-R mutants employed in this
study were 1^ wt EPO-R, 2^ v268^276 EPO-R, 3^ v256^267 EPO-R, 4^ 1^276 EPO-R, 5^ 1^276 (F272A) EPO-R, 6^ v+9 EPO-R, 7^ v+9
(F272A) and 8^ 1^267 EPO-R. The transmembrane (TM) region is indicated. Amino acids at positions 268^276 are depicted as a white box,
the F to A substitution at position 272 is indicated as a vertical line, deletions are indicated. B: Expression of EPO-Rs in COS 7 cells. COS
7 cells transiently transfected with EPO-R cDNAs were pulse labeled for 30 min with [35S]Cys/Met and were lysed in 500 Wl PBS containing
1% Triton, 0.5% deoxycholate and 5 mM EDTA, in the presence of protease inhibitors. Cell lysates were immunoprecipitated with antibodies
against the extracellular domain of the EPO-R, followed by the addition of protein A^Sepharose. Subsequently, samples were separated by
10% SDS^PAGE, and autoradiographed. Molecular weight markers in kDa are depicted on the left. The EPO-R derivatives in lanes 1^8 corre-
spond to mutants 1^8, depicted in (A). The bracket points at truncated EPO-R derivatives (lanes 4^8), the arrowhead points at wt, v268^276
and v256^267 EPO-Rs (lanes 1^3).
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defective in its capacity to endocytose EPO, whereas 1^276
EPO-R (Fig. 1A) can internalize EPO to a similar extent as wt
EPO-R [14]. To address whether these nine amino acids con-
fer receptor-mediated 125I-EPO internalization we generated
an EPO-R mutant (v+9 EPO-R; Fig. 1A), truncated at amino
acid 255 onto which amino acid residues 268^276 were li-
gated. The rationale for preparing this mutant was double:
(a) to rule out that impaired endocytosis by 1^267 EPO-R was
merely due to the extent of truncation of the EPO-R; (b) to
establish whether amino acids 268^276 on their own, were
su⁄cient to confer receptor-mediated 125I-EPO internaliza-
tion. Even though 1^267 EPO-R was defective in its capacity
to internalize 125I-EPO [14], it was necessary to establish that
the membrane proximal cytosolic amino acids located N-ter-
minus to residue 267 are not required for EPO endocytosis in
context of the full-length EPO-R. For that purpose, we con-
structed v256^267 EPO-R (Fig. 1A). It also served as a con-
trol for v+9 EPO-R, since both receptors (v256^267 EPO-R
and v+9 EPO-R) lacked residues 256^267; in v256^267 EPO-
R the remaining intact cytosolic domain was attached whereas
in v+9 EPO-R only the nine amino acid residues
FEGLFTTHK were attached. To determine whether F272
contributes to the internalization process, 1^276 (F272A)
and v+9 (F272A) EPO-Rs were generated (Fig. 1A). In addi-
tion, v268^276 EPO-R (Fig. 1A) was engineered to resolve the
contribution of amino acids 268^276 to EPO endocytosis and
signaling in context of the full-length receptor.
EPO endocytosis via the EPO-R was essentially similar in
di¡erent cellular systems [14,15], supporting the notion that
this process relies mainly on intrinsic properties of the recep-
tor molecule and not on the cell type in which it is expressed.
We have previously shown [14] that while the kinetics of
125I-EPO internalization by EPO-R and truncated EPO-Rs
were similar, the level of maximum endocytosis was lower in
the truncated, endocytosis-de¢cient EPO-R mutants. Thus,
there was a correlation between the general pro¢le of maxi-
mum endocytosis when one wave of endocytosis was mea-
sured and when the experiment was performed for 75 min
at 37‡C. Thus, here we measured continuous internalization
of 125I-EPO in COS 7 cells transfected with the panel of EPO-
Rs depicted in Fig. 1A. Expression of the corresponding re-
ceptors was veri¢ed by immunoprecipitation of metabolically
labeled EPO-Rs (Fig. 1B).
COS 7 cells transiently transfected with the panel of EPO-R
mutants (Fig. 1A) were incubated at 37‡C in the presence of
125I-EPO for 75 min and the amount of internalized versus cell
surface-associated 125I-EPO was determined. Wt and 1^276
EPO-Rs were employed as positive controls in comparison
to 1^267 EPO-R, which served as a reference for an endocy-
tosis-defective receptor. Results are plotted as the percent of
cell surface associated or intracellular 125I-EPO, with respect
to the total amount of cell-associated (surface plus intracellu-
lar) 125I-EPO. As shown in Fig. 2 the ratio of internalized
125I-EPO to that bound on the cell surface was approximately
1 for wt, v268^276, v256^267, 1^276 and v+9 EPO-Rs,
whereas the ratio ranged from 0.5 to 0.7 for 1^257 (data
not shown and [14]), 1^267, v+9 (F272A), and 1^276
(F272A) EPO-Rs.
The fact that 125I-EPO internalization via v+9 EPO-R was
essentially similar to wt EPO-R implies that the membrane
proximal cytosolic amino acid stretch 268^276 harbors a se-
quence or structure motif that confers receptor-mediated li-
gand endocytosis. Impaired endocytosis of 125I-EPO via v+9
(F272A) points out that Phe 272 contributes to this process.
Deletion of residues 268^276 from the full-length EPO-R did
not abrogate 125I-EPO internalization, suggesting the presence
of additional endocytosis motifs in the EPO-R cytosolic do-
main.
3.2. Down regulation of cell surface EPO-Rs in the absence of
ligand
To determine whether amino acids 268^276 are also in-
volved in constitutive ligand-independent down regulation of
cell surface EPO-R, we measured down regulation of cell sur-
face EPO-Rs in the absence of ligand under conditions in
which protein synthesis is blocked [16] (Fig. 3). It should be
noted that these experimental conditions do not account for
Fig. 2. Binding and internalization of 125I-EPO by EPO-Rs. COS 7
cells expressing EPO-R variants were incubated in the presence of
125I-EPO for 75 min at 37‡C. Speci¢c binding was determined by
subtracting the measured counts in the presence of cold ligand from
those in its absence. The ¢lled and empty bars represent the ratio of
cell-surface bound and internalized 125I-EPO respectively, to the to-
tal amount of 125I-EPO, which was associated with the cells. The ra-
tio of internalized to surface 125I-EPO for each EPO-R represents
the mean of at least three identical experiments, performed in tripli-
cates.
Fig. 3. Constitutive down regulation of cell surface EPO-Rs. COS 7
cells transfected with EPO-R cDNAs were incubated in the presence
of CHX (100WM) at 37‡C for the duration of the experiment. Cells
were collected 30, 60, 120 and 240 min (8U106 cells for each time
point) following addition of CHX. Cells were subjected to 125I-EPO
binding at 4‡C. The graph represents the means ( þ S.E.M.) of three
identical experiments. Filled squares, triangles, circles and empty in-
verted triangles represent 1^267, v+9 (F272A), wt and 1^257 EPO-
Rs, respectively. Empty squares, triangles and circles represent 1^
276, v+9 and v268^276 EPO-Rs, respectively.
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di¡erences between the receptor mutants, which may include
the rate of their arrival to the cell surface or later sorting.
Transfected COS 7 cells were incubated with CHX, and cells
were collected 30, 60, 120 and 240 min thereafter. Binding of
125I-EPO was performed at 4‡C for at least 10 h, thereby
reaching saturation of cell surface receptors. The results of
this experiment (Fig. 3) demonstrate that the rate of down
regulation is most aberrant for 1^257 and 1^267 EPO-Rs,
which once at the cell surface appear to be rather stable.
These data are in line with the higher cell surface levels of
these EPO-R derivatives [14]. Cell surface 1^257 and 1^267
EPO-Rs declined by 30% after 4 h of CHX treatment, prob-
ably re£ecting ‘bulk internalizationP, whereas all the other
EPO-Rs declined by 50^60%. Since down regulation of cell
surface v+9 EPO-R was similar to that of wt EPO-R, we
suggest that amino acid residues 268^276 may also contribute
to ligand-independent down regulation. The pro¢le of v268^
276 EPO-R down regulation implies that additional determi-
nants of the EPO-R are involved in this process. Notably, cell
surface v+9 (F272A) EPO-R was down regulated with similar
kinetics as wt EPO-R. Therefore, unlike its contribution to the
ligand-mediated endocytosis, F272 does not seem essential for
ligand-independent EPO-R down regulation.
3.3. Involvement of amino acids 256^276 in EPO-mediated
signal transduction
To resolve whether amino acid residues 268^276 of the
EPO-R are essential for signal transduction via the receptor,
the IL-3-dependent pro-B cell line Ba/F3 was employed. When
these cells are transfected with the EPO-R cDNA they can
respond to EPO with faithful signal transduction, prolifera-
tion and partial erythroid di¡erentiation [29]. This experimen-
tal system has been extensively utilized for studying the bio-
chemistry, tra⁄cking and signal transduction via the EPO-R.
Ba/F3 cells were stably transfected with the cDNAs of v256^
267, v268^276 and wt EPO-Rs in pXM. Cell lines were gen-
erated from each transfection, and subjected to biochemical
analysis. Both v256^267 and v268^276 EPO-Rs expressing
Ba/F3 cells grew in WEHI containing media, (data not
shown) yet their proliferation in EPO was abrogated (Fig.
4A). Cell surface levels of the EPO-R derivatives on the Ba/
F3 cells were similar (data not shown), as were their total
cellular levels (Fig. 4B).
The amino acid deletion in v256^267 EPO-R spans the
majority of box 1 [30], required for JAK2 activation, thereby
explaining its inability to support EPO-mediated proliferation.
Amino acid residues 268^276 are located penultimate to box 1
in the segment bridging box 1 and box 2. This segment also
contains Trp at position 282, which is crucial for EPO-medi-
ated signal transduction [31]. The inability of v268^276 EPO-
R to support EPO-mediated proliferation of Ba/F3 cells
points out the involvement of this segment in EPO-mediated
signaling. This is, in addition to amino acids 280^300, the
deletion of which was found to block EPO-mediated signal
transduction via the respective receptor (v280^300 EPO-R
(PB)) [32].
As a ¢rst step towards characterizing the molecular block in
signal transduction via v256^267 and v268^276 EPO-Rs we
examined the ability of these EPO-Rs to activate JAK2. Using
bicistronic retrovirus vectors, we stably expressed wt, v256^
267 and v268^276 EPO-Rs in Ba/F3 cells. These vectors con-
tain the IRES and GFP downstream; the level of expression
of GFP (monitored by FACS) and that of the EPO-R are
strongly correlated [21,24]. Ba/F3 cells expressing wt, v256^
267 or v268^276 EPO-Rs were sorted by £ow cytometry and
subjected to stimulation with 100 U/ml of EPO for 7 min (Fig.
5). Cell lysates were immunoprecipitated with anti-EPO-R or
anti-JAK2 antibodies. The immunoprecipitates were subjected
to Western blot analysis with anti-P-Tyr antibodies (upper
two panels), or anti-JAK2 antibodies (lower panel). As shown
in Fig. 5, stimulation of Ba/F3 cells expressing v256^267 or
v268^276 EPO-Rs did not result in Tyr phosphorylation of
either EPO-R (Fig. 5, upper panel) or of JAK2 (Fig. 5, middle
panel). The Western blot of JAK2 immunoprecipitates was
subsequently probed with anti-JAK2 antibodies (Fig. 5, lower
panel). Hence, the inability of ligand-bound v256^267 and
Fig. 4. Residues 268^276 of the EPO-R are required for EPO-medi-
ated proliferation. Ba/F3 cells expressing wt, v256^267 or v268^276
EPO-Rs cloned in pXM were cultured in the presence of EPO and
proliferation was determined by the methylthiazol^tetrazolium meth-
od (A) [43]. The white and gray bars represent proliferation of Ba/
F3 cells expressing v256^267 or v268^276 EPO-Rs, respectively, as
calculated with respect to the proliferation of Ba/F3 cells expressing
wt EPO-R, referred to as 100% (black bars). Receptor expression
was veri¢ed by Western blot analysis with antibodies directed
against the extracellular portion of the EPO-R (B). Non-transfected
Ba/F3 cells (NT) are depicted as control.
Fig. 5. Residues 256^276 of the EPO-R are required for EPO-medi-
ated activation of JAK2. Ba/F3 cells expressing wt or mutant EPO-
Rs, cloned in the pMX-IRES-GFP bicistronic retroviral vector,
were depleted of IL-3 for 4 h prior to stimulation with 100 U/ml
EPO for 7 min. Cell lysates were immunoprecipitated with antibod-
ies against EPO-R or JAK2 followed by Western blot analysis using
anti-P-Tyr (PY) or anti-JAK2 antibodies as indicated.
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v268^276 EPO-Rs to mediate JAK2 Tyr phosphorylation as
well as their inability to undergo EPO-induced Tyr phosphor-
ylation was consistent with their inability to proliferate in
EPO (Fig. 4).
To pinpoint individual amino acid residues within the seg-
ment 268^276 of the EPO-R which are crucial for signal trans-
duction, we mutated both Phe residues 268 and 272 of the
EPO-R to Ala. Ba/F3 cell lines stably expressing F268,272A
EPO-R in pXM were generated, and their proliferation in a
wide range of EPO concentrations as well as EPO-induced
Tyr phosphorylation of the receptor was determined (Fig.
6). As shown in Fig. 6A, F268,272A EPO-R did not support
proliferation of Ba/F3 cells in EPO. EPO-mediated Tyr phos-
phorylation of cellular proteins (Fig. 6B) as well as EPO-
mediated Tyr phosphorylation of F268,272A EPO-R was
not detected (Fig. 6C). These data support the notion that
Phe residues 268 and/or 272 are essential for EPO-mediated
signal transduction.
4. Discussion
Previous studies by us [14] and by others [15], employing
truncated EPO-Rs have identi¢ed a membrane proximal intra-
cellular motif, which is essential for EPO internalization. In
this study we examined the capacity of this membrane prox-
imal motif (amino acids 268^276) to confer EPO endocytosis
and down regulate cell surface EPO-R and demonstrated its
requirement for EPO-mediated signal transduction.
The amino acid stretch 268^276 harbors an endocytosis
motif as shown by its capacity to augment 125I-EPO internal-
ization when attached to a truncated EPO-R (v+9) compared
to ligand internalization mediated by 1^267 EPO-R. Di-Leu-
based motifs [33,34], as well as Phe-based motifs have been
documented to participate in endocytosis [35]. Hence, amino
acid residues Leu^Phe (positions 271, 272) within the amino
acid stretch 268^276 may constitute an endocytosis motif [36].
Impaired ligand internalization via v+9 (F272A) and 1^276
(F272A) EPO-Rs suggests that Phe 272 is crucial for ligand-
mediated endocytosis, conferred by this motif. It has been
shown that Ser phosphorylation upstream of di-Leu motifs
may contribute to the capacity of cell surface receptors to
internalize the ligand [33]. The question of whether the two
Ser residues located upstream to amino acid residues 268^276
are phosphorylated remains to be addressed. Tyr-based motifs
probably do not play a role in EPO endocytosis via the re-
ceptor, since an EPO-R in which all cytosolic Tyr residues
were replaced by Phe endocytosed the ligand to the same
extent as wt EPO-R [15]. Furthermore, 1^276 EPO-R, which
endocytoses EPO to a similar extent as wt EPO-R, does not
contain any Tyr residues [14]. Thus, it appears that endocy-
tosis of EPO via the receptor occurs even with constructs
which do not elicit signaling [15], as was also shown for the
growth hormone receptor [37].
Using a panel of truncated EPO-R mutants others [15] and
we [14] have suggested the existence of endocytosis motifs in
the membrane proximal intracellular region of the EPO-R.
Both studies however did not address the activity of this seg-
ment on its own and in context of the full-length receptor,
points which are tackled here. Although residues 268^276
harbor a motif, which mediates endocytosis of EPO and con-
fers down regulation of cell surface receptors, deletion of this
region from the intact EPO-R did not inhibit endocytosis of
EPO or down regulation of the receptor from the cell surface.
These data suggest that other cytosolic domains in the EPO-R
are involved in ligand endocytosis and down regulation of cell
surface receptor and function either in conjunction to 268^276
or assume activity upon excision of 268^276 from the recep-
tor. The uninterrupted endocytosis of EPO via v268^276
EPO-R is in line with other experimental systems in which
excision of an internalization determinant from the intact re-
ceptor did not impair ligand internalization, pointing to the
presence of more than one major signal for internalization [9].
Amino acids 268^276 comprise a portion of the segment,
which bridges the box 1 and the box 2 regions of the EPO-R.
The contribution of the cytosolic region £anking box 1 and
box 2 of the EPO-R for JAK2 activation has previously been
suggested [32,38]. Excision of amino acid residues 280^300, or
amino acid residues 267^293 penultimate to box 2, abolished
EPO-mediated proliferation [32,38] and EPO-induced JAK2
binding and Tyr phosphorylation of the EPO-R [32].
The ¢nding that a truncated EPO-R which contains box 1
and the domain £anking box 1 and box 2, yet lacks box 2,
possesses EPO-mediated mitogenic activity [39] supports the
notion that the segment 268^276 is essential for signal trans-
duction. The lack of response to EPO of Ba/F3 cells express-
ing F268,272A EPO-R demonstrates the participation of these
Phe residues in EPO-driven signal transduction. Our data are
in line with the recent demonstration that residues 259^284
harbor essential motifs for JAK2 binding and activation [40].
Amino acid residues 268^276 also conferred ligand-indepen-
dent down regulation from the cell surface of an EPO-R,
Fig. 6. F268,272A EPO-R does not support proliferation of Ba/F3
cells in EPO. A: Ba/F3 cells expressing F268,272A or wt EPO-Rs
cloned in pXM (squares and circles, respectively; 0.8U106 cells/ml)
were incubated in the presence of increasing concentrations of EPO
for 24 h. Cell proliferation was determined by the methylthiazol^tet-
razolium method. The experiment represents one of four identical
experiments performed in triplicate. Ba/F3 cells expressing
F268,272A or wt EPO-Rs were treated with EPO (100 U/ml) for 10
min. Cell lysates were immunoprecipitated with anti-PY (B), or
anti-EPO-R (C,D) antibodies, and separated on 10% SDS^PAGE
gel, followed by immunoblot analysis with anti-PY (B,C) or anti-
EPO-R (D) antibodies.
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which lacks the vast majority of the cytosolic domain (v+9
EPO-R). As excision of this segment did not impair constitu-
tive down regulation of the respective receptor molecule
(v268^276 EPO-R) we postulate that additional receptor seg-
ments participate in this process. Unlike the case for receptor-
mediated internalization of 125I-EPO, mutation of F272 to A
did not abrogate constitutive down regulation of cell surface
v+9 EPO-R (F272A) or 1^276 (F272A) (data not shown),
suggesting the involvement of distinct structural requirements
and/or intracellular pathways in constitutive versus ligand-
mediated receptor internalization. One may speculate that
Phe 272 participates in the generation of a signaling compe-
tent conformation of the EPO-R. This conformation may also
be required for receptor-mediated ligand endocytosis but not
for constitutive down regulation of cell surface EPO-Rs.
For the growth hormone and IL-2 receptors, two other
members of the cytokine receptor family, it has been demon-
strated that ligand internalization may occur via detergent-
resistant membrane domains [41,42]. These studies and our
data direct future attempts to determine the route of EPO
endocytosis and to compare the intracellular fate of EPO,
which is internalized by the various EPO-R mutants.
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